SR One Capital Fund I Aggregator LP 4
4 · Design Therapeutics, Inc. · Filed Apr 1, 2021
Insider Transaction Report
Form 4
SR One Capital Fund I Aggregator LP
10% Owner
Transactions
- Conversion
Common Stock
2021-03-30+4,439,839→ 4,439,839 total - Conversion
Common Stock
2021-03-30+936,637→ 5,376,476 total - Purchase
Common Stock
2021-03-30$20.00/sh+250,000$5,000,000→ 5,626,476 total - Conversion
Series A Preferred Stock
2021-03-30−7,236,938→ 0 total→ Common Stock (4,439,839 underlying) - Conversion
Series B Preferred Stock
2021-03-30−1,526,718→ 0 total→ Common Stock (936,637 underlying)
Footnotes (3)
- [F1]The Series A Preferred Stock and the Series B Preferred Stock were converted into Common Stock on a 1.63-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The reported securities are held directly by SR One Capital Fund I Aggregator, LP. SR One Capital Partners I, LP is the general partner of SR One Capital Fund I Aggregator, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Partners I, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Partners I, LP, SR One Capital Management, LLC and Mr. George may each be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- [F3]SR One Capital Fund I Aggregator, LP purchased 250,000 shares of Common Stock of Design Therapeutics, Inc. (the "Issuer") in connection with the Issuer's public offering.